126 episódios

Advances in Women’s Health addresses advances, breakthroughs and treatments for conditions related to women’s health, as well as preventive measures physicians can advise their patients to pursue. Topics will include breast health as it relates to cancer, ethnicity, fertility and pregnancy; osteoporosis; female athletes’ health and emotional issues; pregnancy and all facets related to it; aging; nutrition and health; eating disorders; alternative medicine; and sex education.

Advances in Women's Health ReachMD

    • Ciência

Advances in Women’s Health addresses advances, breakthroughs and treatments for conditions related to women’s health, as well as preventive measures physicians can advise their patients to pursue. Topics will include breast health as it relates to cancer, ethnicity, fertility and pregnancy; osteoporosis; female athletes’ health and emotional issues; pregnancy and all facets related to it; aging; nutrition and health; eating disorders; alternative medicine; and sex education.

    Investigating Combination Therapies for Triple-Negative Breast Cancer

    Investigating Combination Therapies for Triple-Negative Breast Cancer

    Host: Mario R. Nacinovich, Jr., MSc

    Guest: Sara Tolaney MD, MPH


    Triple-negative breast cancer comprises up to 20 percent of all breast cancer diagnoses, and unfortunately, survival for these patients has been more limited than in other subtypes of disease. That’s why improving outcomes for patients with triple-negative breast cancer has been the focus of recent studies—much like the one investigating eribulin and pembrolizumab that Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute, presented at the 2020 ASCO Annual Meeting.

    Emerging Roles for Immunotherapy in HER2+ Breast Cancer

    Emerging Roles for Immunotherapy in HER2+ Breast Cancer

    Guest: Sara Tolaney MD, MPH


    What do we know now about the potential safety and tolerability of administering T-DM1 with pembrolizumab to patients with HER2+ breast cancer? Breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School Dr. Sara Tolaney explains these findings from her study that was presented at the 2020 ASCO Annual Meeting.

    New Treatment Strategies for HER2+ Breast Cancer: The Latest from ASCO

    New Treatment Strategies for HER2+ Breast Cancer: The Latest from ASCO

    Guest: Sara Tolaney MD, MPH


    There are several new strategies that have been emerging to treat patients with HER2+ breast cancer, and here to walk us through those that were highlighted at the 2020 ASCO Annual Meeting is Dr. Sara Tolaney, breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at the Harvard Medical School.

    Monitoring Adjuvant Chemotherapy in Elderly Women with Triple Negative Breast Cancer

    Monitoring Adjuvant Chemotherapy in Elderly Women with Triple Negative Breast Cancer

    Host: Matt Birnholz, MD

    Guest: Slavica Janeva, MD


    Despite the increasing number of elderly patients diagnosed with breast cancer, few clinical trials focus on this age group. That’s why Dr. Slavica Janeva's team focused on the impacts of adjuvant chemotherapy on survival rates in this patient population, the results of which may change clinical practice paradigms moving forward, as he discusses with Dr. Matt Birnholz.

    Investigating the Impact of Cannabidiol on Breast Cancer Cell Viability

    Investigating the Impact of Cannabidiol on Breast Cancer Cell Viability

    Host: Matt Birnholz, MD

    Guest: Luka Dobovisek, MD


    Though cannabidiol (CBD) has long been recognized in the oncological field as a palliative therapeutic agent, only recently has it been demonstrated to induce anti-tumor responses in breast cancer. To learn more, Dr. Matt Birnholz is joined by Dr. Luka Dobovisek, whose recent study looked at the effect of CBD on cell viability of selected breast cancer cell lines, both as a single agent and in combinations with breast cancer therapies such as tamoxifen.

    Investigating the Link Between Sexual Activity & Menopause Onset

    Investigating the Link Between Sexual Activity & Menopause Onset

    Host: Paul Doghramji, MD

    Guest: Megan Arnot


    Menopause is an inevitable transition in every woman’s life, but what if engaging in a basic physiological need like sex could delay its onset? Researching this potential connection is Megan Arnot, a Ph.D. candidate in the Department of Anthropology at the University College London. As the lead author of the study, she walks us through her findings and the range of factors they investigated, like the type of sexual activity and whether or not women lived with a partner.

Top podcasts em Ciência

Ouvintes também assinaram

Mais de ReachMD